IL17A and rheumatoid arthritis: Therefore, anti-IL-17A Ab (secukinumab) was administered to patients with RA, and a high dose of secukinumab (150 mg every 4 weeks) showed a higher achievement rate for the primary endpoint (ACR20 response) than the placebo group [156].